Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report

Yingying Sun, Chengcheng Wu, Chunyan Liu, Zonghong Shao
Clinical Laboratory 2020 July 1, 66 (7)
32658429

BACKGROUND: Elderly patients with acute leukemia have high mutation frequency and are often accompanied by various underlying diseases, so treatment is difficult and mortality is high.

METHODS: We report an elderly acute myeloid leukemia patient with a complex karyotype who received a reduced dose of decitabine in induction chemotherapy due to a combination of severe heart disease.

RESULTS: After a course of induction chemotherapy, the patient achieved complete cytogenetic remission. Cardiac function did not deteriorate during or after chemotherapy.

CONCLUSIONS: Dose-reduced decitabine alone can be effective and safe in the induction chemotherapy for elderly AML patients with complex karyotype.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
32658429
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"